In an open‑label 8‑week pilot trial, thematic analysis of interviews with 17 people with major depressive disorder found that many participants reported enhanced self‑determination, increased connectedness, clearer cognitive processing and improved emotional well‑being that they linked to reduced depressive symptoms. However, responses were heterogeneous—some reported negative effects or no benefit—and the open‑label design without a placebo control limits causal conclusions and emphasises the need for careful dosing and realistic expectations.
- Published
- Journal
- Therapeutic Advances in Psychopharmacology
- Authors
- Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L., Forsyth, A., Evans, W., Hoeh, N. R., Sundram, F., Menkes, D., Muthukumaraswamy, S., Reynolds, L.